REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ironfist Therapeutics (“Ironfist”), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor-associated macrophages without a targeting ligand, will present positive preclinical proof-of-concept results for 177Lu-Tamrada at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26), taking place October 17–21, 2026, in Vienna, Austria. In an orthotopic syngeneic model of pancr
